In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Woes Raise Big Pharma R&D Question

Executive Summary

GSK's various thwarted efforts to boost productivity through R&D revamps begs the question whether big pharma should be trying to do in-house discovery and early development at all.


Related Content

Biopharma R&D Productivity And Growth 2017: Big Pharma Closes The Gap
GSK Bags Barron As R&D Boss As Vallance Joins UK Government
Walmsley Shakes Up GSK; Cuts More Than 30 Drug Development Programs
J&J’s Approach To Sourcing Innovation: Closing The Networking Gap
GSK CEO Andrew Witty Under Fire About China During Q2 Call
GSK Says R&D Productivity Up, But Story Is About Culture, Not Numbers
GlaxoSmithKline R&D Under Scrutiny In Bid For Fresh Funding
Putting The Pieces Together Again: GSK Creates End-To-End Business Units
GSK Tries to Mimic Real-World Biotech
R&D Productivity at GSK? He CEDD, She CEDD


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts